5 January 2024
Sidley Represented Resolian in its Acquisition of China-Based Bioanalytical CRO Denali Medpharma
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ruchun Ji Lead | Sidley | Partner | Corporate and M&A | Not stated |
| Jing Peng | Sidley | Senior associate | Corporate and M&A | Not stated |
| Ling Chen | Sidley | Counsel | Corporate and M&A | Not stated |
| Chen Yang | Sidley | Counsel | Regulatory | Not stated |
| Mulai Xu | Sidley | Senior associate | Regulatory | Not stated |
| Oliver Currall | Sidley | Partner | Tax | Not stated |
| Patrick Harrison | Sidley | Partner | Antitrust | Not stated |
| Iva Todorova | Sidley | Associate | Antitrust | Not stated |
| Fiona Shajko | Sidley | Associate | Antitrust | Not stated |
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- ResolianBuy-side
- Counterparties
- Denali Medpharma (Target)